

1 **Determinants of treatment success among drug-susceptible tuberculosis patients in Ghana:**  
2 **A prospective cohort study**

3  
4  
5 Richard Delali Agbeko Djochie<sup>1</sup>, Berko Panyin Anto<sup>1, \*</sup>, Mercy Naa Aduale Opare-Addo<sup>1</sup>

6 <sup>1</sup>Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, College  
7 of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

8  
9  
10  
11  
12  
13  
14 \*Corresponding author

15 Email: [bpanto.pharm@knust.edu.gh](mailto:bpanto.pharm@knust.edu.gh), [berkopanyin@hotmail.com](mailto:berkopanyin@hotmail.com) (BPA)

16 ORCID ID: 0000-0002-4673-4929

## 30 **Abstract**

### 31 **Background**

32 Achieving optimal rates of success in tuberculosis treatment is vital not just for the individual  
33 patient's well-being but also for preventing the rise of drug-resistant tuberculosis strains.  
34 Unfavourable treatment outcomes pose significant challenges for healthcare systems worldwide.  
35 Identifying the factors that determine treatment success is crucial for implementing effective  
36 interventions that enhance treatment outcomes and contribute to the eradication of the disease. As  
37 a result, this study aimed to assess tuberculosis treatment outcomes and identify factors associated  
38 with treatment success.

### 39 **Methods**

40 Patients diagnosed with active tuberculosis were closely monitored from the start of their treatment  
41 until its completion from January 2021 to June 2022. A data collection tool, developed using  
42 Redcap and aligned with the study objectives, was utilized to gather demographic information, and  
43 adverse reactions to antitubercular medicines and track the treatment outcomes of the participants.  
44 The participants' quality of life was assessed using the Short-form 12 version 2 questionnaire at  
45 baseline, as well as at the end of the second and sixth months. Logistic regression was employed  
46 to evaluate the association between various participant characteristics and treatment success, with  
47 odds ratios used to quantify the strength of the associations.

### 48 **Results**

49 Among 378 participants, 77.3% had successful TB treatment, while 13.5% were lost to follow-up,  
50 0.5% experienced treatment failure, and 8.7% died. Factors influencing treatment success included  
51 initial body weight, weight gain during treatment, HIV status, drug adverse reactions, and mental  
52 well-being at the beginning of treatment. Multivariate analysis showed that gaining at least 3kg  
53 during treatment and having no risk of depression at the beginning significantly increased the  
54 likelihood of successful treatment.

### 55 **Conclusion**

56 Patients with tuberculosis who experience compromised physical and mental health-related quality  
57 of life, encounter adverse reactions to antitubercular drugs and have concurrent HIV infection

58 should receive close monitoring and personalized interventions to improve their chances of  
59 treatment success.

60 **Keywords:** Tuberculosis; treatment outcomes; health-related quality of life; Ghana

61

## 62 **Introduction**

63 Tuberculosis (TB) remains a pressing global health concern, affecting more than 10 million people  
64 each year [1]. Despite being a preventable and treatable infection, TB ranks as the second deadliest  
65 disease worldwide, only behind COVID-19 with 1.5 million fatalities in 2021 alone. The majority  
66 of TB cases occur in low- and middle-income countries within the World Health Organisation's  
67 (WHO) regions of South-East Asia, Africa, and the Western Pacific [1]. In 2021, Ghana reported  
68 136 tuberculosis cases per 100,000 individuals, resulting in approximately 12,000 deaths attributed  
69 to TB only and 3,700 TB/HIV coinfection deaths [2]. The impact of the COVID-19 pandemic on  
70 healthcare services may have exacerbated this situation [1].

71 Tuberculosis treatment success rates exhibit significant variations across different countries and  
72 regions. As of 2020, the global TB treatment success rate stood at 85%, short of the End TB  
73 Strategy target of 90% by 2025 [1]. In the United States, it was reported at 74%, while the African  
74 Region averaged at 79% [1,3]. Adverse treatment outcomes for drug-susceptible TB cases pose a  
75 significant challenge to healthcare systems worldwide. Achieving optimal treatment success rates  
76 is not only essential for individual patient well-being but also for preventing the emergence of  
77 drug-resistant TB strains. Despite free TB treatment accessibility in Ghana, the mortality rate  
78 associated with this disease remains a concern. Since 2012, Ghana's TB treatment success rate has  
79 plateaued at 84-85% [4,5], falling short of WHO's recommended target of 90% [6]. Studies in  
80 Ghana, primarily retrospective in design, report varying treatment success rates across regions:

81 82.5% in the Volta region, 90.2% in the Central region, and 90.7% in the Greater Accra region  
82 [7,8]. Prioritizing strategies to enhance treatment success is vital for the National Tuberculosis  
83 Control Program (NTP) to reduce re-treatment needs, save costs, and lower morbidity and  
84 mortality rates.

85 In lower- to medium-income countries, studies have identified factors contributing to unfavourable  
86 TB treatment outcomes, including limited access to health logistics, nonadherence to treatment,  
87 HIV coinfection, alcohol use, and drug abuse [9–11]. Other authors have also highlighted a  
88 premature sense of recovery before completing the treatment, the absence of social support,  
89 persistent stigma, and limited knowledge about TB as factors associated with adverse treatment  
90 outcomes [12,13]. A systematic review found socioeconomic elements such as inadequate housing  
91 (characterized by overcrowding and poor ventilation), malnutrition, and alcohol abuse as negative  
92 influences on TB treatment outcomes [14].

93 Tuberculosis treatment success is influenced by a complex interplay of sociodemographic and  
94 clinical factors including low income, substance abuse, gender disparities, education level,  
95 unemployment, advanced age, membership in migratory communities, and the stigma surrounding  
96 TB, which collectively shape the outcomes of TB treatment programmes [14–16]. Evaluating TB  
97 treatment outcomes and identifying the root causes is essential for health authorities and  
98 policymakers.

99 While numerous studies have delved into the factors influencing low treatment success rates in  
100 Ghana, it's important to note that much work remains to be done in this field. Although some  
101 contributing factors to successful treatment outcomes, such as age and pretreatment weight, have  
102 been identified, there is still a critical need to expand the scope of research in order to gain a more  
103 comprehensive understanding of these complex dynamics [12,13,17]. Most of these studies,

104 predominantly retrospective in design, have yet to fully consider the impact of health-related  
105 quality of life and the occurrence of adverse reactions to anti-TB drugs on treatment outcomes.  
106 Therefore, there is a need for further research efforts to explore these factors in greater depth,  
107 ultimately paving the way for more effective interventions to improve TB treatment success rates  
108 in Ghana and similar settings. Consequently, this study aimed to assess treatment outcomes and  
109 identify factors associated with success in patients with drug-susceptible TB taking into  
110 consideration the impact of anti-TB adverse drug reactions and health-related quality of life. The  
111 findings will contribute to the body of knowledge in TB management and provide evidence for  
112 health managers and policymakers to develop tailored interventions for specific demographics.  
113 These interventions aim to tackle the less-than-optimal rates of treatment success and ultimately  
114 reduce the burden of TB within the country and similar global settings.

115

## 116 **Methods**

### 117 **Study design and participants**

118 This study was conducted in the Eastern and Ashanti Regions of Ghana, specifically at eight  
119 tuberculosis treatment centres. These centres were chosen based on their consistent reporting of  
120 the highest number of TB cases annually in their respective regions over the past five years. The  
121 study sites consisted of three primary care hospitals and one regional referral hospital. The study  
122 population included newly diagnosed TB patients who were eligible for drug treatment and ready  
123 to initiate TB treatment. However, only patients who were 18 years of age or older, had access to  
124 a mobile phone and provided their consent by signing a consent form were included. Conversely,  
125 individuals with psychiatric conditions, liver or kidney impairment were excluded from the study.

126 To ensure sufficient statistical power with an 80% power analysis, a two-tailed test, an alpha level  
127 of 0.05, and a medium effect size of 0.5, a minimum of 128 participants was required for this study.  
128 However, considering potential non-responses and ensuring a diverse representation of  
129 tuberculosis patients, 378 respondents were recruited.

## 130 **Data collection and analysis**

131 The data collection instrument utilized in this study was developed using REDCap, aligning with  
132 the study objectives. To ensure its reliability, the instrument underwent validation and was  
133 pretested in a hospital that was not part of the main study. The feedback received from the pretest  
134 was utilized to make necessary adjustments to the instrument.

135 Participant recruitment and data collection were conducted from 10<sup>th</sup> January 2021 to 15<sup>th</sup> April  
136 2022. Trained research assistants called each participant, contacting them at least once a week to  
137 inquire about any adverse effects resulting from their TB treatment. Additionally, any adverse drug  
138 reactions (ADRs) recorded on the participants' TB treatment cards at the clinic were extracted. A  
139 list of side effects associated with antitubercular drugs, documented in the literature, was used to  
140 screen the participants. The Naranjo ADR Probability Scale was employed to determine the causal  
141 relationship between the reported ADRs and the antitubercular drugs. Confirmation of a causal  
142 relationship was established in scenarios where a patient experienced the same reaction after re-  
143 administration of the drug, when the reaction only occurred following drug administration, when  
144 the reaction subsided or ceased after the administration of an antidote, and when the patient was  
145 not taking any alternative medication known to cause the same reaction [18]. Only ADRs classified  
146 as Certain (a score of  $\geq 9$ ), Probable (a score of 5-8), or Possible (a score of 1-4) were included in  
147 the analysis. The severity of antitubercular drug-related adverse reactions (ADRs) in participants  
148 was assessed using Hartwig's ADR severity scale and categorized as severe (levels 5-7) if they led

149 to death, in-patient hospitalization, or prolonged hospital stay; moderate (levels 3-4) if they  
150 required withholding or discontinuation of anti-TB treatment and/or an antidote; and mild (levels  
151 1-2) if they necessitated suspending anti-TB drugs without an antidote [19,20]. For analysis  
152 purposes, moderate-to-severe ADRs were grouped as major ADRs, while mild ADRs were  
153 considered minor ADRs.

154 The Short-form 12 version 2 questionnaire (SF-12v2) was employed in this study to assess the  
155 participants' quality of life at baseline, as well as at the end of the second and sixth months. The  
156 SF-12v2 survey consists of 12 items that measure various aspects of functioning and well-being  
157 from the patient's perspective. This questionnaire is a validated and widely accepted tool for  
158 evaluating the quality of life in individuals aged 18 and above, particularly in the context of chronic  
159 illnesses [21,22]. The validity of the SF-12v2 as a health-related quality-of-life evaluation  
160 instrument has also been confirmed among Ghanaian adults [23]. For comparative analysis, the  
161 physical component summary (PCS) and mental component summary (MCS) scores were utilized  
162 in the current study [22]. A higher PCS or MCS score indicates a better quality of life. A minimum  
163 clinically important difference (MCID) in quality of life at the end of treatment was defined as a  
164 3-point increase in PCS or MCS scores while participants with an MCS score below 42 were  
165 classified as experiencing depression [22].

## 166 **Statistical analysis**

167 Data cleansing was executed with Microsoft Excel 2016, and subsequently, data analysis was  
168 conducted using IBM SPSS Statistics (version 21). The findings were presented in the form of  
169 frequencies, percentages, and means with standard deviations. Chi-squared or Fisher's exact test,  
170 was applied to identify socio-demographic and clinical factors linked to treatment success. Logistic  
171 regression analysis, incorporating both crude and adjusted odds ratios, was utilised to gauge the

172 strength of any observed associations between patient characteristics and treatment success. The  
173 threshold for statistical significance was established at less than 0.05.

## 174 **Ethical considerations**

175 The study was conducted following ethical guidelines and was approved by two committees. The  
176 Ghana Health Service Ethics Review Committee granted approval with the number GHS-ERC  
177 007/11/20 on January 2, 2021, and the Committee on Human Research, Publications, and Ethics  
178 of Kwame Nkrumah University of Science and Technology approved it with the number  
179 CHRPE/AP/171/21 on April 27, 2021.

180 Throughout the study, ethical principles were upheld. These principles included ensuring voluntary  
181 participation, beneficence, nonmaleficence, privacy, and confidentiality. Participants were fully  
182 informed and willingly chose to participate. They also provided written informed consent.  
183 Importantly, participants had the right to withdraw from the study at any time, and they were not  
184 required to provide a reason for doing so.

## 185 **Results**

### 186 **Sociodemographic characteristics of participants**

187 Among the 378 participants, the majority were male (67.2%), married (44.2%), and employed  
188 (75%), with a mean age of 45.3 ( $\pm$ 15.1) years. As shown in Table 1, 12.9% were illiterate, and a  
189 small proportion of participants had extrapulmonary TB (6.1%), were smokers (6.4%), consumed  
190 alcohol (25.4%), or were HIV-positive (25.7%).

191

192



193 *Table 1 Sociodemographic and clinical characteristics of study participants*

<b>Characteristics</b>	<b>Frequency <i>n</i></b>	<b>Percentage of total</b>
<b>Age (years)</b>		
18 – 25	26	6.9
26 – 35	84	22.2
36 – 45	90	23.8
46 – 55	90	23.8
56 – 65	49	13.0
≥66	39	10.3
<b>Gender</b>		
Male	254	67.2
Female	124	32.8
<b>Marital status</b>		
Married	167	44.2
Single	127	33.6
Divorced	41	10.9
Widowed	43	11.3
<b>Employment status</b>		
Employed	289	76.5
Unemployed	89	23.5
<b>Educational level</b>		
Basic	230	60.9
Secondary	70	18.5
Tertiary	29	7.7
None	49	12.9
<b>Type of TB</b>		
Pulmonary TB	350	92.6
Extra-pulmonary TB	23	6.1
Both	5	1.3
<b>Smoking status</b>		
Smoker	24	6.4
Nonsmoker	354	93.6
<b>Alcohol use</b>		
Yes	96	25.4
No	282	74.6
<b>HIV status</b>		
HIV positive	97	25.7
HIV negative	275	72.8
HIV status unknown	6	1.5
<b>Baseline HRQOL</b>		
Depression	97	25.7
Physical impairment	298	78.8
<b>ADR Status</b>		
No ADR	198	52.4
Minor ADR	68	18.0
Major ADR	112	29.6

194 TB = Tuberculosis, HIV = Human immune-deficiency virus, ADR = Adverse drug reaction, HRQOL = health-related quality of  
195 life

## 196 **Treatment outcomes of study participants**

197 The distribution of tuberculosis treatment outcomes among the study participants was as follows:  
198 44.2% were cured, 33.1% completed their therapy, 13.5% were lost to follow-up, 8.7% died, and  
199 0.5% were classified as treatment failures. Therefore, the overall treatment success rate in this  
200 study was 77.3%.

201 As illustrated in Table 2, gender did not significantly affect treatment success, with 78.7% of males  
202 and 74.2% of females achieving successful treatment ( $p = 0.322$ ). However, a notable difference  
203 was observed based on participants' baseline weight, where those with a weight of at least 53kg  
204 had a significantly higher success rate (83.6%) compared to those with less weight (72.6%) ( $p =$   
205  $0.011$ ). Furthermore, the amount of weight gained during treatment had a substantial influence on  
206 treatment success. Participants who gained a minimum of 3kg during treatment demonstrated a  
207 remarkable success rate of 90.9%, while those who gained less than 3kg had a success rate of  
208 65.5% ( $p < 0.001$ ). Other factors, such as alcohol use, tobacco smoking, and the initiation of Highly  
209 Active Antiretroviral Treatment (HAART) before tuberculosis, did not show statistically  
210 significant associations with treatment success. However, participants with HIV-negative status  
211 exhibited a significantly higher success rate (81.8%) compared to those with HIV-positive status  
212 (64.9%) ( $p = 0.002$ ). Additionally, the type of HIV infection (HIV-1, HIV-2, or both) had a  
213 significant impact on treatment success, with HIV-2-infected participants demonstrating the  
214 lowest success rate (57.1%) compared to the other groups ( $p = 0.011$ ). Regarding the site of TB  
215 infection, those with extrapulmonary TB achieved a 100% success rate, while participants with  
216 pulmonary TB had a success rate of 75.4% ( $p = 0.003$ ).

217

218 *Table 2 Association between patient characteristics and treatment success*

<b>Parameter</b>	<b>Number of participants</b>	<b>% of patients with treatment success</b>	<b>p-value</b>
<b>Gender</b>			
Male	254	78.7	0.322
Female	124	74.2	
<b>Weight at baseline</b>			
< 53kg	219	72.6	0.011
≥ 53kg	159	83.6	
<b>Total weight gained</b>			
< 3kg	174	65.5	<0.001
≥ 3kg	170	90.9	
<b>Alcohol use</b>			
Yes	96	72.9	0.241
No	282	78.7	
<b>Tobacco smoking</b>			
Yes	24	83.3	0.462
No	354	76.8	
<b>HIV status</b>			
HIV-positive	97	64.9	0.002
HIV-negative	275	81.8	
HIV status unknown	6	66.7	
<b>HIV Type</b>			
HIV-1	83	69.9	0.011
HIV-2	7	57.1	
Both HIV-1 & 2	7	14.3	
<b>Site of TB infection</b>			
Pulmonary	350	75.4	0.003
Extra-pulmonary	28	100.0	
<b>HAART started before TB</b>			
Yes	84	72.0	0.133
No	13	57.4	
<b>ADR status</b>			
No ADR	198	77.3	0.991
At least one ADR	180	77.2	
<b>Physical HRQOL at baseline</b>			
Good physical health	76	88.8	0.006
Poor physical health	302	74.2	
<b>Mental HRQOL at baseline</b>			
Good mental health	281	80.2	0.026
Poor mental health	97	69.1	

219 WHO=World Health Organization; MCS=mean component summary; PCS=physical component summary; HIV=human  
 220 immunodeficiency virus; HAART=highly active antiretroviral treatment; TB=tuberculosis; ADR = adverse drug reaction.

221

222

223 The presence or absence of adverse reactions to antitubercular drugs didn't make a significant  
224 difference in the success rates of treatment. The success rates were quite similar at 77.3% for those  
225 with adverse reactions and 77.2% for those without ( $p = 0.991$ ). Additionally, the severity of these  
226 adverse reactions also did not affect the treatment outcomes.

227 However, when looking at participants who experienced minor and major adverse reactions  
228 separately, their success rates were 80.9% and 75.0%, respectively ( $p = 0.362$ ). So, the severity of  
229 the adverse reactions didn't seem to impact success significantly.

230 On the other hand, the initial physical health of participants did have a notable impact on the  
231 treatment's success. Those in good physical health had a significantly higher success rate of 88.8%,  
232 compared to those in poor physical health, who had a success rate of 74.2% ( $p = 0.006$ ). Similarly,  
233 the initial mental health of participants also played a role, with those in good mental health  
234 achieving a higher success rate of 80.2%, while those in poor mental health had a lower success  
235 rate of 69.1% ( $p = 0.026$ ).

## 236 **Determinants of treatment success**

237 The robustness of the relationships between patient characteristics and the success of treatment, as  
238 depicted in Table 3, reveals significant findings. Participants with a baseline weight above 53 kg  
239 exhibited 1.9 times higher odds of achieving treatment success compared to those with a weight  
240 of 53 kg or less, with an odds ratio (OR) of 1.9 (95% CI: 1.2 – 3.2,  $p = 0.012$ ). Additionally,  
241 individuals who gained at least 3 kg during the course of treatment demonstrated significantly  
242 increased odds of treatment success, with an OR of 4.5 (95% CI: 2.2 – 9.0,  $p < 0.001$ ).

243 HIV status played a crucial role in treatment outcomes. HIV-negative participants had more than  
244 twice the odds of achieving treatment success compared to their HIV-positive counterparts, with

245 an OR of 2.4 (95% CI: 1.4 – 4.1,  $p < 0.001$ ). Furthermore, participants with HIV-1 infection  
 246 showed over four times the odds of success compared to those with HIV-2, with an OR of 4.2  
 247 (95% CI: 1.3 – 3.7,  $p = 0.019$ ).

248

249 *Table 3 The effect of participants' characteristics on the odds of having treatment success*

Patient characteristics	Treatment success		
	OR	95% CI	P-value
<b>Weight at baseline</b>			
≤ 53 kg	1		
>53 kg	1.9	1.2 – 3.2	0.012
<b>Total weight gained during treatment</b>			
<3 kg	1		
≥3 kg	4.5	2.2 – 9.0	<0.001
<b>HIV status</b>			
HIV-positive	1		
HIV-negative	2.4	1.4 – 4.1	<0.001
<b>Type of HIV</b>			
HIV-2	1		
HIV-1	4.2	1.3 – 3.7	0.019
<b>Physical HRQOL at baseline</b>			
Poor physical health	1		
Good physical health	2.5	1.2 – 5.3	0.014
<b>Mental HRQOL at baseline</b>			
Poor mental health	1		
Good mental health	1.8	1.1 – 3.0	0.027
<b>Gastrointestinal ADR</b>			
Yes	1		
No	1.8	1.1 – 3.0	0.019
<b>Hepatobiliary system ADR</b>			
Yes	1		
No	21.8	2.6 – 183.0	0.005

250 ADR = adverse drug reaction; HRQOL = health-related quality of life; HIV = human immunodeficiency virus

251

252 The physical and mental HRQOL at the beginning of treatment significantly influenced outcomes.  
 253 Participants in good physical health had three times higher odds of treatment success compared to  
 254 those in poor physical health, with an OR of 2.5 (95% CI: 1.2 – 5.3,  $p = 0.014$ ). Similarly,

255 individuals in good mental health exhibited nearly twice the odds of success compared to those in  
256 poor mental health, with an OR of 1.8 (95% CI: 1.1 – 3.0,  $p = 0.027$ ).

257 Furthermore, antitubercular ADRs had varying impacts on treatment success. While the severity  
258 of ADRs did not significantly affect treatment outcomes, participants who did not experience  
259 gastrointestinal ADRs had twice the odds of treatment success (OR = 1.8, 95% CI: 1.1 – 3.0,  $p =$   
260 0.019), and those without hepatobiliary system ADRs had a strikingly higher likelihood of  
261 treatment success, with odds almost 22 times greater than those with such ADRs (OR = 21.8, 95%  
262 CI: 2.6 – 183.0,  $p = 0.005$ ).

263 A multivariate analysis considering all statistically significant factors related to treatment success  
264 indicated that gaining at least 3kg of body weight at the end of treatment ( $p = 0.004$ ) and not being  
265 at risk of depression at the beginning of treatment ( $p = 0.016$ ) remained significantly associated  
266 with a successful treatment outcome.

267 While this study observed that a higher proportion of males, non-smokers, non-drinkers, and  
268 patients receiving Highly Active Antiretroviral Treatment (HAART) tended to have improved  
269 treatment outcomes, it's important to note that these distinctions did not attain statistical  
270 significance.

## 271 **Discussion**

272 The TB treatment success rate in this study stood at 77.3%, comprising 44.2% of participants who  
273 were cured and 33.1% who completed their treatment. This rate fell below both the national  
274 average of 84% [6] and the WHO's target of 90% [8]. It also trailed behind the success rates of  
275 81.8%, 81.0% and 90.2% reported in studies conducted in Somalia [24], India [26], and another  
276 study within the Central region of Ghana [7]. Nonetheless, it exceeded the success rates reported

277 in certain Ethiopian studies (71.4% and 60.1%) [25,27] as well as the 68.5% reported by a ten-  
278 year retrospective study conducted in the Ashanti Region of Ghana [17].

279 Among the participants, 22.8% experienced adverse treatment outcomes, including 13.5% who  
280 were lost to follow-up, 8.7% who died, and 0.5% who had treatment failure. The loss to follow-up  
281 rate in this study was similar to the 6.2% observed in Somalia [24] and the 8% reported in Ethiopia  
282 [25]. However, it was lower than the 21.3% found in another Ethiopian study [27] and the 12.5%  
283 in an Indian study [26] but higher than the 0.9% reported in another Ghanaian study [7]. Defaulting  
284 on TB treatment not only worsens symptoms to the point of requiring hospitalization but also poses  
285 a public health risk by potentially spreading drug-resistant strains of Mycobacterium. Therefore,  
286 it is crucial to provide comprehensive pre-treatment adherence counselling and continue  
287 reinforcing it during clinic visits [28].

288 Among the 33 participants who died during TB treatment, 63.6% (n=21) were HIV-positive. The  
289 TB death rate (8.7%) observed in this study was lower than the 10% target set by the TB strategic  
290 plan [29], 17.7% reported in Ethiopia [27], and 10.1% in another Ethiopian study [30]. However,  
291 it was higher than the 4.17% in a Pakistani study [31] and the 2% reported in India [26].  
292 Tuberculosis infection accelerates the progression of acquired immune deficiency syndrome  
293 (AIDS) in HIV-positive individuals [32], making them more vulnerable to opportunistic infections  
294 that require additional treatment. In contrast, tuberculosis patients without HIV infection generally  
295 achieve better treatment outcomes [10,24,27,30,33]. This is due to the detrimental effect of HIV  
296 infection on CD4 cell counts and overall immunity, which impairs successful treatment. The higher  
297 pill burden and potential drug interactions associated with HIV treatment contribute to increased  
298 nonadherence rates and lower rates of treatment success.

299 Importantly, the type of HIV infection influences treatment outcomes, with HIV-1 patients having  
300 more than double the odds of achieving successful treatment outcomes compared to those with  
301 HIV-2 infection. This finding aligns with a prospective study conducted in Guinea Bissau, which  
302 found that HIV-infected patients showed greater clinical severity of tuberculosis [32]. It  
303 underscores the significance of promptly diagnosing and treating HIV in tuberculosis patients, as  
304 well as offering continuous adherence support and psychological counselling during treatment for  
305 individuals living with HIV, to ensure treatment success.

306 Unlike certain studies conducted in the African region [25,27], this study reveals a notable positive  
307 correlation between extrapulmonary TB and treatment success. In our study, all participants with  
308 extrapulmonary TB achieved successful treatment outcomes, aligning with findings from  
309 analogous studies conducted in Bhutan and Ethiopia [34,35]. Further research is needed to  
310 comprehensively understand the relationship between the type of TB infection and treatment  
311 success.

312 The importance of increasing body weight in TB patients through proper nutrition to improve their  
313 physical health and treatment outcomes has been widely recognized [36–39]. This study confirms  
314 that patients who had a baseline weight of over 53kg or gained at least 3kg of body weight during  
315 treatment achieved successful outcomes, consistent with findings from Peru and Ethiopia [39,40].  
316 The positive impact of weight gain on treatment outcomes can be attributed to improved nutrition,  
317 which strengthens the immune system and supports the healing process. Therefore, offering  
318 nutritional support to vulnerable TB patients, such as those experiencing homelessness or living  
319 in impoverished households, could significantly enhance their chances of treatment success.

320 Participants who did not have physical impairment at the beginning of treatment had nearly three  
321 times higher odds of achieving a successful treatment outcome compared to those with physical



322 impairment. Similarly, patients without a risk of depression at baseline had almost twice the odds  
323 of treatment success. It is crucial for healthcare workers dealing with TB to identify such patients  
324 and provide them with adequate counselling to address the psychosocial and emotional challenges  
325 associated with the disease. Additionally, effectively managing comorbidities that could cause  
326 physical impairment can improve patients' physical strength and increase their likelihood of  
327 treatment success. Implementing interventions to eliminate stigma within communities is also  
328 highly recommended.

329 We found no significant association between the rate of treatment success among participants who  
330 did not experience any anti-TB drug reactions and those who had at least one ADR. Moreover, the  
331 difference in treatment success rate among participants who had minor ADRs and those who had  
332 major ADRs was not statistically significant. This suggests that the severity of adverse drug  
333 reactions did not appear to significantly influence treatment outcomes in this study. However, it  
334 was observed that participants who did not develop any gastrointestinal adverse drug reactions had  
335 twice the odds of treatment success compared to those who did. Similarly, participants who did  
336 not experience any hepatobiliary system adverse drug reactions had 22 times the odds of treatment  
337 success compared to those who did. These findings align with two prospective studies conducted  
338 in India and China, which also reported that the absence of antitubercular adverse drug reactions  
339 significantly correlated with treatment success [41,42]. To fully understand the role of  
340 gastrointestinal and hepatobiliary ADRs in determining TB treatment success, further research is  
341 required.

## 342 **Conclusion**

343 This study highlights several key factors that significantly influence treatment outcomes in drug-  
344 susceptible tuberculosis cases: including baseline weight, weight gain during treatment, HIV

345 status, mental and physical health, and the presence of gastrointestinal and hepatobiliary system  
346 adverse drug reactions. Recognizing and addressing these determinants can guide healthcare  
347 professionals in tailoring interventions to enhance treatment success rates, ultimately contributing  
348 to the battle against tuberculosis.

## 349 **Acknowledgement**

350 The authors are grateful to the managers of the hospitals in the study sites and all TB patients  
351 who willingly participated in the study.

## 352 **References**

- 353 [1] WHO. Global TB Report 2022. Geneva: 2022.
- 354 [2] WHO. Tuberculosis profile: Ghana 2021.  
355 [https://worldhealthorg.shinyapps.io/tb\\_profiles/?\\_inputs\\_&entity\\_type=%22country%22&](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22GH%22)  
356 [lan=%22EN%22&iso2=%22GH%22](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22GH%22) (accessed January 4, 2023).
- 357 [3] Teferi MY, El-Khatib Z, Boltena MT, Andualem AT, Asamoah BO, Biru M, et al.  
358 Tuberculosis treatment outcome and predictors in Africa: a systematic review and meta-  
359 analysis. *Int J Environ Res Public Health* 2021;18:10678.
- 360 [4] Palmer VE. Ghana: Strategic Focus. CDC Division of Global HIV & TB Country Profile  
361 2022. <https://www.cdc.gov/globalhivtb/where-we-work/Ghana.pdf> (accessed September  
362 22, 2022).
- 363 [5] WHO. Global Tuberculosis Report 2019. Geneva: 2019.
- 364 [6] WHO. The End TB Strategy. Geneva: 2015.
- 365 [7] Otchere J, Ayi I, Tetteh AK, Bimi L, Agyarko E. An Evaluation of Treatment Outcomes  
366 in a Cohort of Clients on the DOTS Strategy, 2012–2016. *Tuberc Res Treat* 2018.  
367 <https://doi.org/10.1155/2018/4287842>.
- 368 [8] Ohene SA, Fordah S, Dela Boni P. Childhood tuberculosis and treatment outcomes in  
369 Accra: A retrospective analysis. *BMC Infect Dis* 2019;19:1–9.  
370 <https://doi.org/10.1186/S12879-019-4392-6/TABLES/4>.
- 371 [9] Chaves Torres NM, Quijano Rodríguez JJ, Porras Andrade PS, Arriaga MB, Netto EM.  
372 Factors predictive of the success of tuberculosis treatment: A systematic review with  
373 meta-analysis. *PLoS One* 2019;14:e0226507.

- 374 [10] Getie A, Alemnew B. Tuberculosis treatment outcomes and associated factors among  
375 patients treated at Woldia General Hospital in Northeast Ethiopia: An institution-based  
376 cross-sectional study. *Infect Drug Resist* 2020;13:3423–9.  
377 <https://doi.org/10.2147/IDR.S275568>.
- 378 [11] Amo-Adjei J, Awusabo-Asare K. Reflections on tuberculosis diagnosis and treatment  
379 outcomes in Ghana. *Archives of Public Health* 2013;71:22. <https://doi.org/10.1186/2049-3258-71-22>.
- 381 [12] Appiah MA, Arthur JA, Gborgblorvor D, Asampong E, Kye-Duodu G, Kamau EM, et al.  
382 Barriers to tuberculosis treatment adherence in high-burden tuberculosis settings in  
383 Ashanti region, Ghana: a qualitative study from patient’s perspective. *BMC Public Health*  
384 2023;23:1317.
- 385 [13] Osei E, Oppong S, Adanfo D, Doepe BA, Owusu A, Kupour AG, et al. Reflecting on  
386 tuberculosis case notification and treatment outcomes in the Volta region of Ghana: a  
387 retrospective pool analysis of a multicentre cohort from 2013 to 2017. *Glob Health Res*  
388 *Policy* 2019;4:1–13. <https://doi.org/10.1186/S41256-019-0128-9/TABLES/3>.
- 389 [14] Lee J-Y, Kwon N, Goo G, Cho S. Inadequate housing and pulmonary tuberculosis: a  
390 systematic review. *BMC Public Health* 2022;22:1–12.
- 391 [15] Nidoi J, Muttamba W, Walusimbi S, Imoko JF, Lochoro P, Ictho J, et al. Impact of socio-  
392 economic factors on Tuberculosis treatment outcomes in north-eastern Uganda: a mixed  
393 methods study. *BMC Public Health* 2021;21:1–16.
- 394 [16] Pradipta IS, Idrus LR, Probandari A, Lestari BW, Diantini A, Alffenaar J-WC, et al.  
395 Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis  
396 setting: a qualitative study from the patient’s perspective. *BMC Public Health* 2021;21:1–  
397 12.
- 398 [17] Agyare SA, Osei FA, Odoom SF, Mensah NK, Amanor E, Martyn-Dickens C, et al.  
399 Treatment Outcomes and Associated Factors in Tuberculosis Patients at Atwima  
400 Nwabiagya District, Ashanti Region, Ghana: A Ten-Year Retrospective Study. *Tuberc*  
401 *Res Treat* 2021;2021:1–9. <https://doi.org/10.1155/2021/9952806>.
- 402 [18] Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for  
403 estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981;30:239–  
404 45.
- 405 [19] Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting  
406 adverse drug reactions. *Am J Hosp Pharm* 1992;49:2229–32.
- 407 [20] Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to  
408 terminology, documentation, and reporting. *Ann Intern Med* 2004;140:795–801.
- 409 [21] Huo T, Guo Y, Shenkman E, Muller K. Assessing the reliability of the short form 12 (SF-  
410 12) health survey in adults with mental health conditions: a report from the wellness

- 411 incentive and navigation (WIN) study. *Health Qual Life Outcomes* 2018;16:34.  
412 <https://doi.org/10.1186/s12955-018-0858-2>.
- 413 [22] Bohannon R, Maljanian R, Landes M. Test-retest reliability of short form (SF)-12  
414 component scores of patients with stroke. *Int J Rehabil Res* 2004;27:149–50.
- 415 [23] Galenkamp H, Stronks K, Mokkink LB, Derks EM. Measurement invariance of the SF-12  
416 among different demographic groups: The HELIUS study. *PLoS One* 2018;13:1–19.  
417 <https://doi.org/10.1371/journal.pone.0203483>.
- 418 [24] Ali MK, Karanja S, Karama M. Factors associated with tuberculosis treatment outcomes  
419 among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in  
420 Mogadishu, Somalia. *Pan African Medical Journal* 2017;28:1–14.  
421 <https://doi.org/10.11604/pamj.2017.28.197.13439>.
- 422 [25] Abebe T, Angamo MT. Treatment outcomes and associated factors among tuberculosis  
423 patients in Southwest Ethiopia. *Gulhane Medical Journal* 2015;57:397–407.  
424 <https://doi.org/10.5455/gulhane.161306>.
- 425 [26] Jain S, Bhagyalaxmi A, Kadri A. Defaulter rate and associated factors among the  
426 Tuberculosis patients treated under DOTS in Ahmedabad City. *Indian J Prev Soc Med*  
427 2012;43:158–64.
- 428 [27] Biruk S, Yimam B, Amdie FZ, Biruk M, Abrha H. Treatment Outcomes of Tuberculosis  
429 and Associated Factors in an Ethiopian University Hospital. *Adv Public Health* 2016.  
430 <https://doi.org/10.1155/2016/8504629>.
- 431 [28] Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors  
432 associated with default from treatment among tuberculosis patients in Nairobi province,  
433 Kenya: A case-control study. *BMC Public Health* 2011;11. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-2458-11-696)  
434 [2458-11-696](https://doi.org/10.1186/1471-2458-11-696).
- 435 [29] MOH. The National Tuberculosis Health Sector Strategic Plan for Ghana: 2015-2020.  
436 Ministry of Health 2015:1–132.
- 437 [30] Zenebe T, Tefera E. Tuberculosis treatment outcome and associated factors among smear-  
438 positive pulmonary tuberculosis patients in Afar, Eastern Ethiopia: a retrospective study.  
439 *Braz J Infect Dis* 2016;20:635–6.
- 440 [31] Tripathi SB, Kapadia VK. Treatment Outcome of Tuberculosis in HIV Seropositive  
441 Patients : an Experience of Southeast Region of Ahmedabad. *National Journal of*  
442 *Community Medicine* 2015;6:462–5.
- 443 [32] Wejse C, Patsche CB, Kühle A, Bamba FJV, Mendes MS, Lemvik G, et al. Impact of  
444 HIV-1, HIV-2, and HIV-1+2 dual infection on the outcome of tuberculosis. *International*  
445 *Journal of Infectious Diseases* 2015;32:128–34.  
446 <https://doi.org/10.1016/j.ijid.2014.12.015>.

- 447 [33] Eshetie S, Gizachew M, Alebel A, Van Soolingen D. Tuberculosis treatment outcomes in  
448 Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A  
449 systematic review and meta-analysis. *PLoS One* 2018;13:1–18.  
450 <https://doi.org/10.1371/journal.pone.0194675>.
- 451 [34] Berhe G, Enquselassie F, Aseffa A. Treatment outcome of smear-positive pulmonary  
452 tuberculosis patients in Tigray Region, Northern Ethiopia. *BMC Public Health* 2012;12:1–  
453 9.
- 454 [35] Jamtsho T, Harries AD, Malhotra S, Wangchuk D, Dophu U, Dorji T, et al. The burden  
455 and treatment outcomes of extra-pulmonary tuberculosis in Bhutan. *Public Health Action*  
456 2013;3:38–42.
- 457 [36] Filate M, Mehari Z, Alemu YM. Longitudinal body weight and sputum conversion in  
458 patients with tuberculosis, Southwest Ethiopia: a retrospective follow-up study. *BMJ*  
459 *Open* 2018;8:e019076. <https://doi.org/10.1136/BMJOPEN-2017-019076>.
- 460 [37] Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-  
461 resistant tuberculosis patients in Ethiopia: A systematic review and meta-analysis.  
462 *International Journal of Infectious Diseases* 2020;98:420–39.  
463 <https://doi.org/10.1016/J.IJID.2020.05.087>.
- 464 [38] Gler MT, Guilatco R, Caoili JC, Ershova J, Cegielski P, Johnson JL. Weight Gain and  
465 Response to Treatment for Multidrug-Resistant Tuberculosis. *Am J Trop Med Hyg*  
466 2013;89:943. <https://doi.org/10.4269/AJTMH.13-0011>.
- 467 [39] Sahile Z, Tezera R, Mariam DH, Collins J, Ali JH. Nutritional status and TB treatment  
468 outcomes in Addis Ababa, Ethiopia: An ambi-directional cohort study. *PLoS One*  
469 2021;16:e0247945. <https://doi.org/10.1371/JOURNAL.PONE.0247945>.
- 470 [40] Krapp F, Véliz JC, Cornejo E, Gotuzzo E, Seas C. Bodyweight gain to predict treatment  
471 outcome in patients with pulmonary tuberculosis in Peru. *The International Journal of*  
472 *Tuberculosis and Lung Disease* 2008;12:1153–9.
- 473 [41] Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse Reactions Due to Directly  
474 Observed Treatment Strategy Therapy in Chinese Tuberculosis Patients: A Prospective  
475 Study. *PLoS One* 2013;8:e65037. <https://doi.org/10.1371/JOURNAL.PONE.0065037>.
- 476 [42] Nagpal M, Devgun P, Kalra RK, Chawla N. Study on the adverse effects affecting  
477 treatment outcome in smear-positive tuberculosis patients under DOTS in Amritsar City.  
478 *Int J Community Med Public Health* 2018;5:801–5. [https://doi.org/10.18203/2394-  
479 6040.ijcmph20180272](https://doi.org/10.18203/2394-6040.ijcmph20180272).
- 480 [43] Kassa JI, Dedefo MG, Korsa AT, Dibessa TT. Factors Affecting Treatment Outcome of  
481 Tuberculosis among Tuberculosis Patients in West Ethiopia. *J Bioanal Biomed* 2018.  
482 <https://doi.org/10.4172/1948-593x.1000200>.

483 [44] Thiruvengadam K, Swaminathan S, Jayapal L, Vedhachalam C, Dusthacker A, Agibothu  
484 Kupparam HK, et al. Factors Influencing Tuberculosis Treatment Outcome in Adult  
485 Patients Treated with Thrice-Weekly Regimens in India. *Antimicrob Agents Chemother*  
486 2017;61:1–12. <https://doi.org/10.1128/aac.02464-16>.

487